Marc Guiu
Overview
Explore the profile of Marc Guiu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
761
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crespo J, Martin-Martin N, Garcia-Longarte S, Corres-Mendizabal J, Carlevaris O, Astobiza I, et al.
Cell Death Dis
. 2024 Jul;
15(7):514.
PMID: 39025841
Prostate cancer exhibits high prevalence and accounts for a high number of cancer-related deaths. The discovery and characterization of molecular determinants of aggressive prostate cancer represents an active area of...
2.
Llorente A, Blasco M, Espuny I, Guiu M, Ballare C, Blanco E, et al.
Nat Cell Biol
. 2023 Nov;
25(12):1833-1847.
PMID: 37945904
MAF amplification increases the risk of breast cancer (BCa) metastasis through mechanisms that are still poorly understood yet have important clinical implications. Oestrogen-receptor-positive (ER) BCa requires oestrogen for both growth...
3.
Linares J, Sallent-Aragay A, Badia-Ramentol J, Recort-Bascuas A, Mendez A, Manero-Ruperez N, et al.
Nat Commun
. 2023 Feb;
14(1):746.
PMID: 36765091
A substantial proportion of cancer patients do not benefit from platinum-based chemotherapy (CT) due to the emergence of drug resistance. Here, we apply elemental imaging to the mapping of CT...
4.
Rivas E, Linares J, Zwick M, Gomez-Llonin A, Guiu M, Labernadie A, et al.
Nat Commun
. 2022 Sep;
13(1):5310.
PMID: 36085201
About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment. Here, we conduct ...
5.
Olivan M, Garcia M, Suarez L, Guiu M, Gros L, Mendez O, et al.
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944822
About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients' quality of life and progresses to lethal PCa in most cases. Hence, understanding the...
6.
Nunez-Olle M, Guiu M, Gomis R
Methods Mol Biol
. 2021 Mar;
2294:253-267.
PMID: 33742407
Metastasis is the main cause of death for cancer patients, but our ability to improve clinical outcome first requires a better understanding of the dynamics, cellular mechanisms, and kinetics of...
7.
Urosevic J, Blasco M, Llorente A, Bellmunt A, Berenguer-Llergo A, Guiu M, et al.
Cancer Res
. 2020 Aug;
80(21):4668-4680.
PMID: 32816905
Carcinoma development in colorectal cancer is driven by genetic alterations in numerous signaling pathways. Alterations in the RAS-ERK1/2 pathway are associated with the shortest overall survival for patients after diagnosis...
8.
Hermanova I, Zuniga-Garcia P, Caro-Maldonado A, Fernandez-Ruiz S, Salvador F, Martin-Martin N, et al.
J Exp Med
. 2020 Mar;
217(6).
PMID: 32219437
Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model...
9.
Gawrzak S, Rinaldi L, Gregorio S, Arenas E, Salvador F, Urosevic J, et al.
Nat Cell Biol
. 2018 Apr;
20(8):990.
PMID: 29674681
In the version of this Article originally published, the boxes framing the two plots in Fig. 1g were misaligned from the axes due to a technical error. This has now...
10.
Gawrzak S, Rinaldi L, Gregorio S, Arenas E, Salvador F, Urosevic J, et al.
Nat Cell Biol
. 2018 Jan;
20(2):211-221.
PMID: 29358704
For many patients with breast cancer, symptomatic bone metastases appear after years of latency. How micrometastatic lesions remain dormant and undetectable before initiating colonization is unclear. Here, we describe a...